tert-butyl (S)-(5-methyl-1-oxohexan-3-yl)carbamate | 86834-95-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (S)-(5-methyl-1-oxohexan-3-yl)carbamate
• 英文别名: tert-butyl N-[(3S)-5-methyl-1-oxohexan-3-yl]carbamate
• CAS: 86834-95-9
• 化学式: C₁₂H₂₃NO₃
• 分子量: 229.32
• InChiKey: PXSPQTFERASGAD-SNVBAGLBSA-N

物化性质

• 沸点：
  323.6±25.0 °C(Predicted)
• 密度：
  0.967±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (S)-(5-methyl-1-oxohexan-3-yl)carbamate 在 N-氯代丁二酰亚胺 、 盐酸羟胺 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 tert-butyl (S)-(1-(isoxazol-3-yl)-4-methylpentan-2-yl)carbamate
  参考文献：
  名称：

  [EN] HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE
  [FR] COMPOSÉS SPIRO HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION

  摘要：

  本公开提供具有抑制G12C突变KRAS蛋白活性的式（I）化合物。本公开还提供包含该化合物的药物组合物，用途和治疗某些疾病的方法，例如癌症，包括但不限于肺癌、胰腺癌和结直肠癌。

  公开号：

  WO2022093856A1
• 作为产物：
  描述：

  tert-butyl (S)-(1-hydroxy-5-methylhexan-3-yl)carbamate 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以0.55 g的产率得到tert-butyl (S)-(5-methyl-1-oxohexan-3-yl)carbamate
  参考文献：
  名称：

  [EN] HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE
  [FR] COMPOSÉS SPIRO HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION

  摘要：

  本公开提供具有抑制G12C突变KRAS蛋白活性的式（I）化合物。本公开还提供包含该化合物的药物组合物，用途和治疗某些疾病的方法，例如癌症，包括但不限于肺癌、胰腺癌和结直肠癌。

  公开号：

  WO2022093856A1

文献信息

• Extensively Stereodiversified Scaffolds for Use in Diversity-Oriented Library Synthesis
  作者：Tiffany Malinky Gierasch、Zhangjie Shi、Gregory L. Verdine

  DOI：10.1021/ol027116f

  日期：2003.3.1

  represents an independently varied stereocenter. These scaffolds provide additional templates for investigations of geometric diversity in library syntheses. Libraries of these N-Fmoc-amino acids were further functionalized by incorporation into a peptide sequence, demonstrating the utility of 12 and 19 as building blocks for diversity oriented synthesis.

  报告了12和19的立体多样性库的合成，其中每个星号代表一个独立变化的立体中心。这些支架为研究文库合成中的几何多样性提供了额外的模板。这些N-Fmoc-氨基酸的文库通过掺入肽序列进一步功能化，证明了12和19作为多样性导向合成的基础材料的实用性。
• Syntheses and biological activities of bombesin analogs modified in the C-terminal dipeptide part
  作者：M Llinares、C Devin、J Azay、G Bergé、JA Fehrentz、J Martinez

  DOI：10.1016/s0223-5234(99)80063-4

  日期：1997.10

  Bombesin receptor antagonists are possible therapeutic agents due to their ability to act as inhibitors of cellular proliferation. On the basis of our hypothesis on the mechanism of action of gastrin associating an activating enzyme system to the receptor and on the results reported in the litterature, we have synthesized bombesin analogues which have been modified in the C-terminal Leu(13)-Leu(14) amide part. We have shown that modification in the C-terminal part of the bombesin strongly affected the biological activity in rat pancreatic acini. The most potent compound which is described here, H-D-Phe- Gln-Trp-Ala-Val-Gly-His-Leu-psi(CH2)Leu-NH2, was able to recognize the bombesin receptor on rat pancreatic acini (Ki 4.3 nM) and antagonized the bombesin stimulated amylase secretion (Ki 7.7 nM).
• “Carba” peptide bond surrogates: synthesis of Boc--Leu-…(CH2-CH2)--Phe-OH and Boc-Leu-ψ-(CH2-CH2)--Phe-OH through a horner-emmons reaction.
  作者：Marc Rodriguez、Annie Heitz、Jean Martinez

  DOI：10.1016/s0040-4039(00)88554-8

  日期：1990.1
• Inhibition of renin by angiotensinogen peptide fragments containing the hydroxy amino acid residue 5-amino-3-hydroxy-7-methyloctanoic acid
  作者：Rodney L. Johnson、Karen Verschoor

  DOI：10.1021/jm00364a019

  日期：1983.10

  The 3R,5S and 3S,5S diastereoisomers of the hydroxy amino acid 5-amino-3-hydroxy-7-methyloctanoic acid (AHMOA) were synthesized from L-leucine and then incorporated into various peptide fragments of angiotensinogen to give the following polypeptides: AHMOA-Val-Phe-OCH3, His-AHMOA-Val-Phe-OCH3, and AHMOA-Ile-His-OCH3. These compounds were tested in an in vitro renin assay system for their ability to inhibit either hog kidney renin or human amniotic renin. The most active analogue of the series was (3R,5S)-AHMOA-Val-Phe-OCH3 (16). Against hog kidney renin, this compound possessed a Ki = 1.7 X 10(-4) M, while against human amniotic fluid, 16 had a Ki = 0.95 X 10(-4) M. The analogues AHMOA-Val-Phe-OCH3 and His-AHMOA-Val-Phe-OCH3 exhibited noncompetitive kinetics when the 3R,5S isomer of AHMOA was employed and competitive kinetics when the 3S,5S diastereoisomer of AHMOA was used.